MetLife Investment Management’s Ironwood Pharmaceuticals IRWD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $405K | Buy |
96,208
+32,441
| +51% | +$125K | ﹤0.01% | 2042 |
|
|
2026
Q1 | $224K | Sell |
63,767
-23,754
| -27% | -$97.4K | ﹤0.01% | 2174 |
|
|
2025
Q4 | $295K | Buy |
87,521
+29,512
| +51% | +$76.6K | ﹤0.01% | 2079 |
|
|
2025
Q3 | $76K | Buy |
+58,009
| New | +$60K | ﹤0.01% | 2744 |
|
|
2025
Q2 | – | Sell |
-67,229
| Closed | -$98.8K | – | 2880 |
|
|
2025
Q1 | $98.8K | Sell |
67,229
-22,026
| -25% | -$52.5K | ﹤0.01% | 2531 |
|
|
2024
Q4 | $395K | Buy |
89,255
+8,559
| +11% | +$34.7K | ﹤0.01% | 1920 |
|
|
2024
Q3 | $332K | Hold |
80,696
| – | – | ﹤0.01% | 2002 |
|
|
2024
Q2 | $526K | Buy |
80,696
+9,126
| +13% | +$64.6K | ﹤0.01% | 1695 |
|
|
2024
Q1 | $623K | Hold |
71,570
| – | – | ﹤0.01% | 1560 |
|
|
2023
Q4 | $819K | Hold |
71,570
| – | – | 0.01% | 1415 |
|
|
2023
Q3 | $689K | Hold |
71,570
| – | – | 0.01% | 1441 |
|
|
2023
Q2 | $762K | Buy |
71,570
+1,442
| +2% | +$15.5K | 0.01% | 1426 |
|
|
2023
Q1 | $738K | Hold |
70,128
| – | – | 0.01% | 1401 |
|
|
2022
Q4 | $869K | Hold |
70,128
| – | – | 0.01% | 1284 |
|
|
2022
Q3 | $727K | Sell |
70,128
-6,005
| -8% | -$68.1K | 0.01% | 1376 |
|
|
2022
Q2 | $878K | Sell |
76,133
-3,116
| -4% | -$36.7K | 0.01% | 1278 |
|
|
2022
Q1 | $997K | Buy |
79,249
+28,288
| +56% | +$324K | 0.01% | 1327 |
|
|
2021
Q4 | $594K | Hold |
50,961
| – | – | ﹤0.01% | 1418 |
|
|
2021
Q3 | $666K | Sell |
50,961
-10,033
| -16% | -$130K | 0.01% | 1365 |
|
|
2021
Q2 | $785K | Hold |
60,994
| – | – | 0.01% | 1304 |
|
|
2021
Q1 | $682K | Buy |
60,994
+296
| +0.5% | +$3.13K | 0.01% | 1349 |
|
|
2020
Q4 | $691K | Sell |
60,698
-9,265
| -13% | -$101K | 0.01% | 1311 |
|
|
2020
Q3 | $629K | Hold |
69,963
| – | – | 0.01% | 1250 |
|
|
2020
Q2 | $722K | Hold |
69,963
| – | – | 0.01% | 1182 |
|
|
2020
Q1 | $706K | Hold |
69,963
| – | – | 0.01% | 1050 |
|
|
2019
Q4 | $931K | Hold |
69,963
| – | – | 0.01% | 1132 |
|
|
2019
Q3 | $601K | Hold |
69,963
| – | – | 0.01% | 1319 |
|
|
2019
Q2 | $765K | Sell |
69,963
-158,146
| -69% | -$1.77M | 0.01% | 1240 |
|
|
2019
Q1 | $2.59M | Buy |
228,109
+152,073
| +200% | +$1.7M | 0.01% | 1119 |
|
|
2018
Q4 | $660K | Hold |
76,036
| – | – | 0.01% | 1202 |
|
|
2018
Q3 | $1.18M | Hold |
76,036
| – | – | 0.01% | 1059 |
|
|
2018
Q2 | $1.22M | Hold |
76,036
| – | – | 0.01% | 949 |
|
|
2018
Q1 | $983K | Hold |
76,036
| – | – | 0.01% | 1015 |
|
|
2017
Q4 | $955K | Buy |
+76,036
| New | +$993K | 0.01% | 1051 |
|
Other funds holding IRWD
AC
SCM
MetLife Investment Management's IRWD Position: Q2 2026 in Review
MetLife Investment Management increased its Ironwood Pharmaceuticals (IRWD) stake by 51% in Q2 2026, buying an estimated $125K and bringing the position to 96,208 shares worth $405K. The position accounts for ﹤0.01% of the portfolio, ranked #2042.
MetLife Investment Management first reported a position in IRWD in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.59M in Q1 2019. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.
- MetLife Investment Management held 96,208 shares of Ironwood Pharmaceuticals worth $405K as of Q2 2026.
- MetLife Investment Management bought 32,441 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $125K.
- Ironwood Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2042 holding.
- MetLife Investment Management first reported a position in Ironwood Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- MetLife Investment Management's Ironwood Pharmaceuticals position peaked at $2.59M in Q1 2019.
- 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.